RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $270 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an 'Outperform' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $270.
September 12, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an 'Outperform' rating on Alnylam Pharmaceuticals and maintained a price target of $270.
The reiteration of an 'Outperform' rating by RBC Capital indicates a positive outlook for Alnylam Pharmaceuticals. The maintained price target of $270 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100